65658-13-1

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazole-4-methanol(9CI) is used as an intermediate in the synthesis of various drugs and pharmaceutical compounds. Its unique structure and functional groups make it a valuable component in the development of new medications with diverse therapeutic properties.
Used in Chemical Industry:
1H-Benzimidazole-4-methanol(9CI) is utilized as a key building block in the production of fine chemicals. Its versatility in organic synthesis allows for the creation of a wide range of chemical products with specific applications in various industries.
Used in Organic Synthesis:
1H-Benzimidazole-4-methanol(9CI) is employed as a versatile starting material in organic synthesis. Its chemical properties and reactivity enable the formation of various complex molecules and compounds, which can be further utilized in different applications.
Used in Research and Development:
1H-Benzimidazole-4-methanol(9CI) is used as a subject of study in research and development for its potential biological activities. Scientists are exploring its therapeutic applications and evaluating its efficacy in treating various diseases and conditions.

InChI:InChI=1/C8H8N2O/c11-4-6-2-1-3-7-8(6)10-5-9-7/h1-3,5,11H,4H2,(H,9,10)

Upstream product

• 312600-95-6 1H-benzo[d]imidazole-4-carboxylic acid hydrochloride 
• 603-81-6 2,3-diaminobenzoic acid 
• 606-18-8 3-nitroanthranilic acid 
• 77326-45-5 2-carbamoyl-3-nitrobenzoic acid 
• 641-70-3 3-nitrophthalic acid anhydride 
• 46006-36-4 benzimidazole-4-carboxylic acid 
• 167487-83-4 ethyl 1H-1,3-benzodiazole-4-carboxylate 
• 37619-25-3 methyl 1H-benzo[d]imidazole-4-carboxylate 

Downstream Products

• 144876-36-8 1H-benzo[d]imidazole-4-carbaldehyde 
• 132873-77-9 4-(bromomethyl)benzimidazole-1-carboxylic acid,1,1-dimethylethyl ester 
• 1352874-02-2 N-{4'-[3-(1H-Benzoimidazol-4-ylmethyl)-6-fluoro-2-imino-2,3-dihydro-benzoimidazol-1-yl]-5-chloro-biphenyl-2-yl}-acetamide 

Relevant academic research and scientific papers

BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS

The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF CIRCADIAN AND DIURNAL RHYTHMS USING PROKINETICIN 2 AGONISTS AND ANTAGONISTS

In alternative embodiments, provided are methods for: modifying circadian rhythmicity or timing in a mammal, treating psychiatric conditions or symptoms due to alterations in a human circadian regulatory system, treating sleep problems in a mammal, or inducing sleep or activity suppression, or causing an arousal or wakening reaction, comprising administration to a mammal or human a compound or composition capable of modifying a prokineticin 2 (PK2) expression or activity, and/or a PKR2 (PK2 receptor), a vasopressin receptor (VR), and/or a melatonin receptor (MR) expression or activity.

TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists

N-Benzyl substitution of phenethylamine 5-HT2A receptor agonists has dramatic effects on binding affinity, receptor selectivity and agonist activity. In this paper we examine how affinity for the 5-HT2A/2C receptors are influenced by N-benzyl substitution of 4-bromo-2,5-dimethoxyphenethylamine derivatives. Special attention is given to the 2′ and 3′-position of the N-benzyl as such compounds are known to be very potent. We found that substitutions in these positions are generally well tolerated. The 2′-position was further examined using a range of substituents to probe the hydrogen bonding requirements for optimal affinity and selectivity, and it was found that small changes in the ligands in this area had a profound effect on their affinities. Furthermore, two ligands that lack a 2′-benzyl substituent were also found to have high affinity contradicting previous held notions. Several high-affinity ligands were identified and assayed for functional activity at the 5-HT2A and 5-HT2C receptor, and they were generally found to be less efficacious agonists than previously reported N-benzyl phenethylamines.

PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES

The invention relates to new derivatives of formula (I) wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of one or more IGF-1R mediated disorders or diseases

BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES

The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of one or more IGF-1R mediated disorders or diseases

HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS

Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

New analogs of nitrobenzylthioinosine

This invention relates to new analogs or derivatives of nitrobenzylthioinosine, use of these new analogs of nitrobenzylthioinosine for the treatment of pain and various other diseases as well as pharmaceuticals comprising at least on new analog of nitrobenzylthioinosine.

Inhibition of nucleoside transport by new analogues of nitrobenzylthioinosine

Nitrobenzylthioinosine (NBTI, 1) was systematically modified by attachment of substituents at positions C6 and N9, and also by substitution of N1 with C. These modifications were chosen to reduce the polarity of the new compounds. Incorporation of the nitro functionality into a benzoxadiazole ring system was considered first. These new nucleosides showed high affinity (1.5-10 nM) towards the nucleoside transport protein as present on human erythrocyte ghosts. Next, modification of this benzoxadiazole ring system with C, S and O in different positions produced a number of less polar nucleosides with affinity in the higher nanomolar range. Modification of N9 was achieved with different alkyl and alcohol substituents. An n-butyl substituent proved best, although all variations yielded substantial decreases in affinity. Replacement of N1 by a carbon atom in combination with a 2-Cl substituent also resulted in a relatively potent NBTI derivative (47 nM).